Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt No Debt
GTXI's Cash to Debt is ranked higher than
78% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. GTXI: No Debt )
GTXI' s 10-Year Cash to Debt Range
Min: 1890.4   Max: No Debt
Current: No Debt

Interest Coverage No Debt
GTXI's Interest Coverage is ranked higher than
78% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GTXI: No Debt )
GTXI' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -40.55
M-Score: 0.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
ROE (%) -207.71
GTXI's ROE (%) is ranked higher than
53% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. GTXI: -207.71 )
GTXI' s 10-Year ROE (%) Range
Min: -397.59   Max: 71.17
Current: -207.71

-397.59
71.17
ROA (%) -163.21
GTXI's ROA (%) is ranked higher than
51% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. GTXI: -163.21 )
GTXI' s 10-Year ROA (%) Range
Min: -156.26   Max: 25.08
Current: -163.21

-156.26
25.08
ROC (Joel Greenblatt) (%) -33077.67
GTXI's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. GTXI: -33077.67 )
GTXI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -14086.91   Max: 522.64
Current: -33077.67

-14086.91
522.64
Revenue Growth (%) -100.00
GTXI's Revenue Growth (%) is ranked higher than
52% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. GTXI: -100.00 )
GTXI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 98.3
Current: -100

0
98.3
» GTXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

GTXI Guru Trades in Q4 2013

Paul Tudor Jones 44,285 sh (New)
Jim Simons 18,480 sh (New)
» More
Q1 2014

GTXI Guru Trades in Q1 2014

Paul Tudor Jones 44,285 sh (unchged)
Jim Simons Sold Out
» More
Q2 2014

GTXI Guru Trades in Q2 2014

George Soros 38,828 sh (New)
Paul Tudor Jones 44,285 sh (unchged)
» More
Q3 2014

GTXI Guru Trades in Q3 2014

George Soros Sold Out
Paul Tudor Jones 36,708 sh (-17.11%)
» More
» Details

Insider Trades

Latest Guru Trades with GTXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-09-30 Sold Out $0.713 - $1.45 $ 0.97-8%0
George Soros 2014-06-30 New Buy$1.3 - $1.66 $ 0.97-31%38828
George Soros 2011-12-31 Sold Out 0.01%$2.36 - $4.61 $ 0.97-72%0
George Soros 2011-09-30 New Buy0.01%$2.78 - $4.92 $ 0.97-75%150000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.00
GTXI's P/B is ranked higher than
76% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. GTXI: 7.00 )
GTXI' s 10-Year P/B Range
Min: 0.44   Max: 32.88
Current: 7

0.44
32.88
EV-to-EBIT -1.81
GTXI's EV-to-EBIT is ranked lower than
52% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GTXI: -1.81 )
GTXI' s 10-Year EV-to-EBIT Range
Min: -18.1   Max: 12.8
Current: -1.81

-18.1
12.8
Current Ratio 5.38
GTXI's Current Ratio is ranked higher than
76% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. GTXI: 5.38 )
GTXI' s 10-Year Current Ratio Range
Min: 3.13   Max: 21.23
Current: 5.38

3.13
21.23
Quick Ratio 5.38
GTXI's Quick Ratio is ranked higher than
77% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. GTXI: 5.38 )
GTXI' s 10-Year Quick Ratio Range
Min: 3.12   Max: 21.22
Current: 5.38

3.12
21.22

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.10
GTXI's Price/Net Cash is ranked higher than
88% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. GTXI: 8.10 )
GTXI' s 10-Year Price/Net Cash Range
Min: 2.7   Max: 307.67
Current: 8.1

2.7
307.67
Price/Net Current Asset Value 8.10
GTXI's Price/Net Current Asset Value is ranked higher than
86% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. GTXI: 8.10 )
GTXI' s 10-Year Price/Net Current Asset Value Range
Min: 2.68   Max: 230.75
Current: 8.1

2.68
230.75
Price/Tangible Book 7.50
GTXI's Price/Tangible Book is ranked higher than
79% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. GTXI: 7.50 )
GTXI' s 10-Year Price/Tangible Book Range
Min: 2.6   Max: 43.95
Current: 7.5

2.6
43.95
Earnings Yield (Greenblatt) -55.20
GTXI's Earnings Yield (Greenblatt) is ranked lower than
51% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. GTXI: -55.20 )
GTXI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -55.2   Max: 3978.9
Current: -55.2

-55.2
3978.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GTU.Germany,
GTx, Inc. is a Delaware corporation incorporated on September 24, 1997. It operates as a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical conditions. The Company develops selective androgen receptor modulators, or SARMs, to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). They are conducting the POWER 1 and POWER 2 (Prevention and treatment Of muscle Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer. The Company is developing GTx-758, an oral luteinizing hormone, or LH, inhibitor for the treatment of advanced prostate cancer. In preclinical in vitro and in vivo models, GTx-758 has demonstrated the potential to reduce testosterone to castrate levels without causing certain estrogen deficiency side effects such as bone loss and hot flashes. The Company's most advanced product candidate, toremifene, is being developed for the prevention of bone fractures and treatment of other estrogen deficiency side effects of ADT in men with prostate cancer and for the prevention of prostate cancer in high risk men with high grade PIN. Additionally the company is developing Capesaris (GTx-758), an oral nonsteroidal selective estrogen receptor (ER) alpha agonist, for secondary hormonal therapy in men with metastatic castration resistant prostate cancer, or CRPC, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy, or ADT. It faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK